IntoCell, Inc. (KOSDAQ:287840)
South Korea · Delayed Price · Currency is KRW 37,750
-1,750 (-4.43%)
At close: Apr 9, 2026
IntoCell Revenue
In the year 2025, IntoCell had annual revenue of 2.30B KRW, down -20.86%. IntoCell had revenue of 728.05M in the quarter ending December 31, 2025, with 547.49% growth.
Revenue
2.30B
Revenue Growth
-20.86%
P/S Ratio
246.65
Revenue / Employee
n/a
Employees
n/a
Market Cap
567.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.30B | -605.91M | -20.86% |
| Dec 31, 2024 | 2.91B | 1.29B | 79.72% |
| Dec 31, 2023 | 1.62B | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 140.03M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 100.17B |
| NIBEC | 32.72B |
| S.Biomedics | 16.55B |
| TiumBio | 12.29B |
| Kangstem Biotech | 3.57B |
| Inventage Lab | 2.94B |
| Y-Biologics | 2.91B |
| curacle co.,ltd. | 7.10M |